Regulatory News In Brief
This article was originally published in The Gray Sheet
Executive Summary
Diagnostics oversight report finalized: In a final 1report released April 30, an HHS advisory committee recommends that FDA "address" all diagnostic tests, genetic or otherwise, using a risk-based framework to determine the appropriate level of regulatory oversight. Diagnostics are currently subject to various levels of oversight from FDA, CMS's 1988 Clinical Laboratory Improvement Amendments (CLIA) and state agencies. FDA, CMS and other agency oversight procedures should be harmonized, the report says. In March 2007, HHS Secretary Michael Leavitt asked the Secretary's Advisory Committee on Genetics, Health and Society (SACGHS) to draft a genetic test oversight report; the draft was released last November. The final report reflects discussions held this February on how best to expand test oversight and health education to address significant gaps that put the public at risk (2"The Gray Sheet" Feb. 25, 2008, p. 14). Lab groups, however, are wary that expanded FDA oversight over all lab-developed tests could lead to redundancies between FDA and CLIA requirements and stifle innovation
You may also be interested in...
Genentech Petition Rekindles Debate On Lab-Developed Test Regulation
A citizen petition from biotech giant Genentech is adding new fire to the debate over whether FDA should regulate more laboratory-developed tests, and under what authority
Genentech Petition Rekindles Debate On Lab-Developed Test Regulation
With lab-developed tests increasing in number and type recently, petition calls for FDA to regulate.
Genentech Petition Rekindles Debate On Lab-Developed Test Regulation
A citizen petition from biotech giant Genentech is adding new fire to the debate over whether FDA should regulate more laboratory-developed tests, and under what authority